Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms

Brady L. Stein, Jason Gotlib, Murat Arcasoy, Marie Huong Nguyen, Neil Shah, Alison Moliterno, Catriona Jamieson, Daniel A. Pollyea, Bart Scott, Martha Wadleigh, Ross Levine, Rami Komrokji, Rebecca Klisovic, Krishna Gundabolu, Patricia Kropf, Meir Wetzler, Stephen T. Oh, Raul Ribeiro, Rita Paschal, Sanjay MohanNikolai Podoltsev, Josef Prchal, Moshe Talpaz, David Snyder, Srdan Verstovsek, Ruben A. Mesa

Research output: Contribution to journalReview article

16 Citations (Scopus)

Abstract

The classical Philadelphia chromosome-negative myeloproliferative neoplasms (MPN), which include essential thrombocythemia, polycythemia vera, and myelofibrosis (MF), are in a new era of molecular diagnosis, ushered in by the identification of the JAK2V617F and cMPL mutations in 2005 and 2006, respectively, and the CALR mutations in 2013. Coupled with increased knowledge of disease pathogenesis and refined diagnostic criteria and prognostic scoring systems, a more nuanced appreciation has emerged of the burden of MPN in the United States, including the prevalence, symptom burden, and impact on quality of life. Biological advances in MPN have translated into the rapid development of novel therapeutics, culminating in the approval of the first treatment for MF, the JAK1/JAK2 inhibitor ruxolitinib. However, certain practical aspects of care, such as those regarding diagnosis, prevention of vascular events, choice of cytoreductive agent, and planning for therapies, present challenges for hematologists/oncologists, and are discussed in this article.

Original languageEnglish (US)
Pages (from-to)424-434
Number of pages11
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume13
Issue number4
DOIs
StatePublished - Apr 1 2015

Fingerprint

Primary Myelofibrosis
Essential Thrombocythemia
Philadelphia Chromosome
Neoplasms
Polycythemia Vera
Mutation
Blood Vessels
Therapeutics
Quality of Life
INCB018424
Oncologists

ASJC Scopus subject areas

  • Oncology

Cite this

Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms. / Stein, Brady L.; Gotlib, Jason; Arcasoy, Murat; Nguyen, Marie Huong; Shah, Neil; Moliterno, Alison; Jamieson, Catriona; Pollyea, Daniel A.; Scott, Bart; Wadleigh, Martha; Levine, Ross; Komrokji, Rami; Klisovic, Rebecca; Gundabolu, Krishna; Kropf, Patricia; Wetzler, Meir; Oh, Stephen T.; Ribeiro, Raul; Paschal, Rita; Mohan, Sanjay; Podoltsev, Nikolai; Prchal, Josef; Talpaz, Moshe; Snyder, David; Verstovsek, Srdan; Mesa, Ruben A.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 13, No. 4, 01.04.2015, p. 424-434.

Research output: Contribution to journalReview article

Stein, BL, Gotlib, J, Arcasoy, M, Nguyen, MH, Shah, N, Moliterno, A, Jamieson, C, Pollyea, DA, Scott, B, Wadleigh, M, Levine, R, Komrokji, R, Klisovic, R, Gundabolu, K, Kropf, P, Wetzler, M, Oh, ST, Ribeiro, R, Paschal, R, Mohan, S, Podoltsev, N, Prchal, J, Talpaz, M, Snyder, D, Verstovsek, S & Mesa, RA 2015, 'Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms', JNCCN Journal of the National Comprehensive Cancer Network, vol. 13, no. 4, pp. 424-434. https://doi.org/10.6004/jnccn.2015.0058
Stein, Brady L. ; Gotlib, Jason ; Arcasoy, Murat ; Nguyen, Marie Huong ; Shah, Neil ; Moliterno, Alison ; Jamieson, Catriona ; Pollyea, Daniel A. ; Scott, Bart ; Wadleigh, Martha ; Levine, Ross ; Komrokji, Rami ; Klisovic, Rebecca ; Gundabolu, Krishna ; Kropf, Patricia ; Wetzler, Meir ; Oh, Stephen T. ; Ribeiro, Raul ; Paschal, Rita ; Mohan, Sanjay ; Podoltsev, Nikolai ; Prchal, Josef ; Talpaz, Moshe ; Snyder, David ; Verstovsek, Srdan ; Mesa, Ruben A. / Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms. In: JNCCN Journal of the National Comprehensive Cancer Network. 2015 ; Vol. 13, No. 4. pp. 424-434.
@article{92d2b0b5cb404d01a414f2c45bb74864,
title = "Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms",
abstract = "The classical Philadelphia chromosome-negative myeloproliferative neoplasms (MPN), which include essential thrombocythemia, polycythemia vera, and myelofibrosis (MF), are in a new era of molecular diagnosis, ushered in by the identification of the JAK2V617F and cMPL mutations in 2005 and 2006, respectively, and the CALR mutations in 2013. Coupled with increased knowledge of disease pathogenesis and refined diagnostic criteria and prognostic scoring systems, a more nuanced appreciation has emerged of the burden of MPN in the United States, including the prevalence, symptom burden, and impact on quality of life. Biological advances in MPN have translated into the rapid development of novel therapeutics, culminating in the approval of the first treatment for MF, the JAK1/JAK2 inhibitor ruxolitinib. However, certain practical aspects of care, such as those regarding diagnosis, prevention of vascular events, choice of cytoreductive agent, and planning for therapies, present challenges for hematologists/oncologists, and are discussed in this article.",
author = "Stein, {Brady L.} and Jason Gotlib and Murat Arcasoy and Nguyen, {Marie Huong} and Neil Shah and Alison Moliterno and Catriona Jamieson and Pollyea, {Daniel A.} and Bart Scott and Martha Wadleigh and Ross Levine and Rami Komrokji and Rebecca Klisovic and Krishna Gundabolu and Patricia Kropf and Meir Wetzler and Oh, {Stephen T.} and Raul Ribeiro and Rita Paschal and Sanjay Mohan and Nikolai Podoltsev and Josef Prchal and Moshe Talpaz and David Snyder and Srdan Verstovsek and Mesa, {Ruben A.}",
year = "2015",
month = "4",
day = "1",
doi = "10.6004/jnccn.2015.0058",
language = "English (US)",
volume = "13",
pages = "424--434",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "4",

}

TY - JOUR

T1 - Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms

AU - Stein, Brady L.

AU - Gotlib, Jason

AU - Arcasoy, Murat

AU - Nguyen, Marie Huong

AU - Shah, Neil

AU - Moliterno, Alison

AU - Jamieson, Catriona

AU - Pollyea, Daniel A.

AU - Scott, Bart

AU - Wadleigh, Martha

AU - Levine, Ross

AU - Komrokji, Rami

AU - Klisovic, Rebecca

AU - Gundabolu, Krishna

AU - Kropf, Patricia

AU - Wetzler, Meir

AU - Oh, Stephen T.

AU - Ribeiro, Raul

AU - Paschal, Rita

AU - Mohan, Sanjay

AU - Podoltsev, Nikolai

AU - Prchal, Josef

AU - Talpaz, Moshe

AU - Snyder, David

AU - Verstovsek, Srdan

AU - Mesa, Ruben A.

PY - 2015/4/1

Y1 - 2015/4/1

N2 - The classical Philadelphia chromosome-negative myeloproliferative neoplasms (MPN), which include essential thrombocythemia, polycythemia vera, and myelofibrosis (MF), are in a new era of molecular diagnosis, ushered in by the identification of the JAK2V617F and cMPL mutations in 2005 and 2006, respectively, and the CALR mutations in 2013. Coupled with increased knowledge of disease pathogenesis and refined diagnostic criteria and prognostic scoring systems, a more nuanced appreciation has emerged of the burden of MPN in the United States, including the prevalence, symptom burden, and impact on quality of life. Biological advances in MPN have translated into the rapid development of novel therapeutics, culminating in the approval of the first treatment for MF, the JAK1/JAK2 inhibitor ruxolitinib. However, certain practical aspects of care, such as those regarding diagnosis, prevention of vascular events, choice of cytoreductive agent, and planning for therapies, present challenges for hematologists/oncologists, and are discussed in this article.

AB - The classical Philadelphia chromosome-negative myeloproliferative neoplasms (MPN), which include essential thrombocythemia, polycythemia vera, and myelofibrosis (MF), are in a new era of molecular diagnosis, ushered in by the identification of the JAK2V617F and cMPL mutations in 2005 and 2006, respectively, and the CALR mutations in 2013. Coupled with increased knowledge of disease pathogenesis and refined diagnostic criteria and prognostic scoring systems, a more nuanced appreciation has emerged of the burden of MPN in the United States, including the prevalence, symptom burden, and impact on quality of life. Biological advances in MPN have translated into the rapid development of novel therapeutics, culminating in the approval of the first treatment for MF, the JAK1/JAK2 inhibitor ruxolitinib. However, certain practical aspects of care, such as those regarding diagnosis, prevention of vascular events, choice of cytoreductive agent, and planning for therapies, present challenges for hematologists/oncologists, and are discussed in this article.

UR - http://www.scopus.com/inward/record.url?scp=84928039932&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928039932&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2015.0058

DO - 10.6004/jnccn.2015.0058

M3 - Review article

C2 - 25870379

AN - SCOPUS:84928039932

VL - 13

SP - 424

EP - 434

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

SN - 1540-1405

IS - 4

ER -